Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07486089 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Name: Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) — clinical trial record (NCT07486089)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUAL-NK-BC

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-02-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

Triple-Negative Breast Cancer

594 trials monitored

See 37 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.

Trial Details

NCT Number	NCT07486089
Lead Sponsor	Beijing Biotech
Conditions	Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Enrollment	60 participants
Start Date	2026-02-02
Primary Completion	2027-02-14 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-03-20